Hims & Hers Health (NYSE:HIMS) Releases Quarterly Earnings Results, Hits Estimates

Hims & Hers Health (NYSE:HIMS) released its quarterly earnings data on Monday. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09, Zacks reports. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. Hims & Hers Health updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Hims & Hers Health Trading Down 2.5%

NYSE:HIMS traded down $1.12 during mid-day trading on Monday, reaching $44.34. 39,694,595 shares of the company’s stock traded hands, compared to its average volume of 32,361,127. Hims & Hers Health has a 12-month low of $19.15 and a 12-month high of $72.98. The firm has a market capitalization of $10.02 billion, a price-to-earnings ratio of 55.43, a PEG ratio of 3.15 and a beta of 2.20. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The company has a 50 day moving average price of $51.39 and a 200-day moving average price of $50.61.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HIMS. Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Canaccord Genuity Group reiterated a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Truist Financial decreased their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Finally, Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Hims & Hers Health presently has an average rating of “Reduce” and an average target price of $38.92.

Insiders Place Their Bets

In related news, CEO Andrew Dudum sold 660,000 shares of the business’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the transaction, the chief executive officer owned 2,214,769 shares in the company, valued at $112,023,016.02. The trade was a 22.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Oluyemi Okupe sold 145,000 shares of the business’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the transaction, the chief financial officer owned 128,984 shares in the company, valued at approximately $7,139,264.40. This represents a 52.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,432,271 shares of company stock worth $74,229,585 in the last quarter. 17.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Man Group plc grew its holdings in shares of Hims & Hers Health by 345.9% during the 2nd quarter. Man Group plc now owns 816,582 shares of the company’s stock worth $40,707,000 after acquiring an additional 633,432 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Hims & Hers Health by 8.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 616,747 shares of the company’s stock worth $30,747,000 after acquiring an additional 46,576 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Hims & Hers Health by 23.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after acquiring an additional 78,543 shares during the period. AQR Capital Management LLC grew its holdings in shares of Hims & Hers Health by 204.7% during the 2nd quarter. AQR Capital Management LLC now owns 390,111 shares of the company’s stock worth $19,193,000 after acquiring an additional 262,089 shares during the period. Finally, California Public Employees Retirement System grew its holdings in shares of Hims & Hers Health by 9.5% during the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after acquiring an additional 29,471 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.